Stockscreener 앱 받기
2.10
4.11%
-0.09
시간 외 거래:
2.10
Entera Bio Ltd 주식(ENTX)의 최신 뉴스
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskel - The Manila Times
Could This Oral Osteoporosis Treatment Replace Daily Injections? Phase 2 Data Reveals Promising Results - StockTitan
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 31.6% in January - MarketBeat
US Penny Stocks: 3 Picks With Market Caps Over $60M - Yahoo Finance
Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat
145,843 Shares in Entera Bio Ltd. (NASDAQ:ENTX) Acquired by Perigon Wealth Management LLC - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 23.1% in January - MarketBeat
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Entera Bio CEO to Present Business Updates at Oppenheimer Healthcare Conference - StockTitan
Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Decrease in Short Interest - Defense World
Entera Bio files Exhibit 5.1 with SEC By Investing.com - Investing.com South Africa
Entera Bio files Exhibit 5.1 with SEC - Investing.com
Entera Bio (NASDAQ:ENTX) Stock Price Up 1.1% – Still a Buy? - Defense World
Entera Bio (NASDAQ:ENTX) Shares Up 1.1%Time to Buy? - MarketBeat
Hypoparathyroidism Market Overview, Trends, Insights, - openPR
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Simply Wall St
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Rises By 19.0% - MarketBeat
Knoll Capital Management, LLC's Strategic Acquisition in Entera Bio Ltd - GuruFocus.com
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update - MarketBeat
FY2024 EPS Estimate for Entera Bio Decreased by Analyst - MarketBeat
HC Wainwright Reaffirms Buy Rating for Entera Bio (NASDAQ:ENTX) - MarketBeat
Entera Bio Ltd. (ENTX) Quarterly 10-Q Report - Quartzy
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Entera Bio Highlights Q3 2024 Financials and FDA Anticipation - TipRanks
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates - The Manila Times
Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Drops By 14.4% - MarketBeat
Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Up 38.4% in September - MarketBeat
Entera Bio outlook steady as H.C. Wainwright backs potential of total hip BMD in osteoporosis care - Investing.com Australia
Entera Bio (NASDAQ:ENTX) Rating Reiterated by HC Wainwright - MarketBeat
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data - MSN
Entera Bio shares hold Buy rating on OXM study success By Investing.com - Investing.com Australia
Entera Bio shares hold Buy rating on OXM study success - Investing.com
Entera Bio's (ENTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com Australia
Entera Bio and OPKO Health report promising obesity treatment study - Investing.com
Entera Bio And Opko Health Provide Update On Pk/Pd Results Of Oral Oxyntomodulin (Glp-1/Glucagon) Peptide Tablet Candidate For Obesity And Metabolic Disorders - XM
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide - EIN News
Entera Bio and OPKO Health Provide Update on PK/PD Results - GlobeNewswire
0.27%
3.05%
자본화:
|
볼륨(24시간):